-

04:00:53 AM

SLDB Stock News

SLDB - Solid Biosciences Inc

10/04/21 8:00 AM

Nasdaq : SLDB

partnership

Solid Biosciences and Forge Biologics Announce Viral Vector Contract Development and cGMP Manufacturing Partnership

Solid Biosciences Inc., a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy, and Forge Biologics, a cell and gene therapy-focused...

RHEA-AI

very positive

09/29/21 7:00 AM

Nasdaq : SLDB

clinical trial

Solid Biosciences Reports Additional Pulmonary Function Results from the Ongoing IGNITE DMD Phase I/II Clinical Trial of SGT-001

- Improvements in two additional assessments of pulmonary function in treated patients compared with untreated control patients further support potential functional benefit of SGT-001 one-year post administration - - Data presented at the Child Neurology Society 50 th Annual Meeting - CAMBRIDGE,

RHEA-AI

neutral

09/23/21 6:00 AM

Nasdaq : SLDB

clinical trial

Solid Biosciences Reports 1.5-Year Data from Patients in the Ongoing IGNITE DMD Phase I/II Clinical Trial of SGT-001

- Data support continued functional benefit 1.5 years post treatment compared with natural history data; assessed by North Star Ambulatory Assessment (NSAA), 6-Minute Walk Test (6MWT) and Forced Vital Capacity (FVC) - - Patient reported outcomes showed sustained improvements at 1.5 years compared

RHEA-AI

neutral

09/20/21 4:05 PM

Nasdaq : SLDB

clinical trial

Solid Biosciences to Provide Update on Long-Term Outcomes Data from Patients in the Ongoing IGNITE DMD Phase I/II Clinical Trial of SGT-001

Solid Biosciences Inc.

RHEA-AI

neutral

09/20/21 4:01 PM

Nasdaq : SLDB

conferences

Solid Biosciences to Participate at Upcoming Investor Conferences

Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Joel Schneider, Ph.D., Chief Operating Officer, and Carl Morris, Ph.D.,

RHEA-AI

neutral

08/24/21 8:00 AM

Nasdaq : SLDB

conferences

Solid Biosciences to Present at the 11th Annual World Orphan Drug Congress USA 2021

Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful

RHEA-AI

neutral

08/19/21 8:05 AM

Nasdaq : SLDB

Solid Biosciences Reports Inducement Grant to New Senior Vice President, Finance

Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the grant of inducement awards to its newly appointed Senior Vice President,

RHEA-AI

very positive

08/19/21 8:00 AM

Nasdaq : SLDB

management

Solid Biosciences Announces Appointment of Michael Inbar, CPA, MBA, as Senior Vice President, Finance

Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Michael Inbar, CPA, MBA, has joined the Company as Senior Vice President,

RHEA-AI

positive

08/16/21 4:11 PM

Nasdaq : SLDB

earnings

Solid Biosciences Provides Second Quarter 2021 Business Update and Financial Results

- Clinical activities underway to advance patient dosing in IGNITE DMD; next patient dosing anticipated in Q4 2021 - - Development activities continue for pipeline initiatives SGT-003 and Ultragenyx collaboration, next generation gene therapy programs for Duchenne patients - - Company ends Q2 with

RHEA-AI

very positive

07/02/21 8:00 AM

Nasdaq : SLDB

clinical trial

Solid Biosciences Reports Inducement Grant to New Senior Vice President, Clinical Development

Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the grant of an inducement award to its newly appointed Senior Vice President,

RHEA-AI

very positive